JCB logo
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online
doi:10.1083/jcb.200904049
The Journal of Cell Biology, Vol. 187, No. 3, 429-442
The Rockefeller University Press, 0021-9525 $30.00
© Brunelle et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 3536K)
Right arrow PDF+supp data (4457K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Brunelle, J. K.
Right arrow Articles by Letai, A.
PubMed
Right arrow Articles by Brunelle, J. K.
Right arrow Articles by Letai, A.
Related Collections
Right arrowRelated In this Issue article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts



Joslyn K. Brunelle1, Jeremy Ryan1, Derek Yecies1, Joseph T. Opferman2, and Anthony Letai1

1 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02052
2 Department of Biochemistry, St. Jude Children’s Research Hospital, Memphis, TN 38105

Correspondence to Anthony Letai: Anthony_Letai{at}dfci.harvard.edu

Myeloid cell leukemia sequence 1 (MCL-1) and B cell leukemia/lymphoma 2 (BCL-2) are anti-apoptotic proteins in the BCL-2 protein family often expressed in cancer. To compare the function of MCL-1 and BCL-2 in maintaining cancer survival, we constructed complementary mouse leukemia models based on Eµ-Myc expression in which either BCL-2 or MCL-1 are required for leukemia maintenance. We show that the principal anti-apoptotic mechanism of both BCL-2 and MCL-1 in these leukemias is to sequester pro-death BH3-only proteins rather than BAX and BAK. We find that the MCL-1–dependent leukemias are more sensitive to a wide range of chemotherapeutic agents acting by disparate mechanisms. In common across these varied treatments is that MCL-1 protein levels rapidly decrease in a proteosome-dependent fashion, whereas those of BCL-2 are stable. We demonstrate for the first time that two anti-apoptotic proteins can enable tumorigenesis equally well, but nonetheless differ in their influence on chemosensitivity.

Abbreviations used in this paper: BCL-2, B cell leukemia/lymphoma 2; BH, BCL-2 homology; MCL-1, myeloid cell leukemia sequence 1.

© 2009 Brunelle et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related In this Issue article

Chemosensitivity depends on the dependency
Ben Short
J. Cell Biol. 2009 187: 314. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents